A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512): stage 1 results

被引：0
|
作者：
Lee, Elizabeth [1 ]
Zhou, Yinglu [2 ]
Hendrickson, Andrea Wahner [3 ]
Fleming, Gini [4 ]
Konstantinopoulos, Panagiotis [1 ]
Krasner, Carolyn [1 ]
Stover, Elizabeth [1 ]
Horowitz, Neil [5 ]
Porter, Rebecca [1 ]
Wright, Alexi [1 ]
Matulonis, Ursula [1 ]
Xiong, Niya [2 ]
Sawyer, Hannah [1 ]
Tayob, Nabihah [2 ]
Liu, Joyce [1 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[2] Dana Farber Canc Inst, Data Sci, Boston, MA 02115 USA
[3] Mayo Clin, Comprehens Canc Ctr, Rochester, MN 55906 USA
[4] Univ Chicago, Med Oncol, Chicago, IL USA
[5] Brigham & Womens Hosp, Div Gynecol Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB009/#156
引用
收藏
页码：A11 / A12
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study.
    Giaccone, Giuseppe
    Thompson, Jillian
    McGuire, Colleen
    Manning, Maria
    Kallakury, Bhaskar
    Chahine, Joeffrey J.
    Subramaniam, Deepa Suresh
    Liu, Stephen V.
    Gibney, Geoffrey Thomas
    Kim, Chul
    McCutcheon, Justine N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck
    Taylor, Matthew H.
    Rasco, Drew W.
    Brose, Marcia S.
    Vogelzang, Nicholas J.
    Richey, Stephen L.
    Cohen, Allen L.
    Richards, Donald A.
    Stepan, Daniel E.
    Dutcus, Corina E.
    Guo, Matthew
    Shumaker, Robert C.
    Schmidt, Emmett V.
    Young, Louise
    Wirth, Lori J.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 174 - 174
  • [23] A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
    Mohamadpour, Maliheh
    Sherman, Eric Jeffrey
    Kriplani, Anuja
    Fetten, James Vincent
    Dunn, Lara
    Michel, Loren S.
    Hung, Kin Wai
    Baxi, Shrujal S.
    McDonald, Erin
    Conybeare, Rachel
    Katabi, Nora
    Ostrovnaya, Irina
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] A phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, Masafumi
    Sung, Max W.
    Kudo, Masatoshi
    Kobayashi, Masahiro
    Baron, Ari D.
    Finn, Richard S.
    Kaneko, Shuichi
    Zhu, Andrew X.
    Kubota, Tomoki
    Kraljevic, Silvija
    Ishikawa, Kohei
    Siegel, Abby B.
    Kumada, Hiromitsu
    Young, Louise
    Okusaka, Takuji
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 105 - 105
  • [25] A Phase 1b trial of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma
    Ikeda, M.
    Sung, M. W.
    Kudo, M.
    Kobayashi, M.
    Baron, A. D.
    Finn, R. S.
    Kaneko, S.
    Zhu, A. X.
    Kubota, T.
    Kraljevic, S.
    Ishikawa, K.
    Siegel, A. B.
    Kumada, H.
    Okusaka, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 37 - 37
  • [26] A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
    Llovet, Josep
    Finn, Richard
    Ikeda, Masfumi
    Sung, Max
    Baron, Ari
    Kudo, Masatoshi
    Okusaka, Takuji
    Kobayashi, Masahiro
    Kumada, Hiromitsu
    Kaneko, Suichi
    Pracht, Marc
    Mamontov, Konstantin
    Meyer, Tim
    Mody, Kalgi
    Kubota, Tomoki
    Dutcus, Corina
    Saito, Kenichi
    Siegel, Abby
    Dubrovsky, Leonid
    Young, Louise
    Zhu, Andrew X.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 189 - 190
  • [27] Characteristics and management of major adverse events in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab based on results from the CLEAR trial
    Motzer, R.
    George, S.
    Merchan, J. R.
    Hutson, T. E.
    Song, X.
    Perini, R. F.
    Xie, R.
    Bapat, U.
    Puente, J.
    ONKOUROLOGIYA, 2023, 19 (02): : 29 - 40
  • [28] Prospective phase II trial of fulvestrant in the treatment of recurrent ovarian carcinoma
    Thomas, S. G.
    Judson, P. L.
    Carson, L. F.
    Downs, L. S.
    Ghebre, R.
    Geller, M. A.
    Jonson, A. L.
    Argenta, P. A.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S32 - S32
  • [29] Impact of Combination Chemotherapy with Itraconazole on Survival for Patients with Recurrent or Persistent Ovarian Clear Cell Carcinoma
    Tsubamoto, Hiroshi
    Sonoda, Takashi
    Yamasaki, Masaaki
    Inoue, Kayo
    ANTICANCER RESEARCH, 2014, 34 (04) : 2007 - 2014
  • [30] Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.
    Matei, Daniela
    Pant, Alok
    Moroney, John William
    Fleming, Gini F.
    Tanner, Edward
    Swetzig, Wendy M.
    Xu, Jiahui
    Cardenas, Horacio
    Kandpal, Manoj
    Gavrilescu, Andreea
    Chen, Siqi
    Kocherginsky, Masha
    Davuluri, Ramana, V
    Zhang, Bin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345